Eric Greig advises clients on market access and reimbursement strategies across the medical device, pharmaceutical, digital health, biotechnology, clinical laboratory, and healthcare services sectors.

Mr. Greig leverages his track record of success in bet-the-company regulatory matters, as well as his extensive experience with health payment systems and innovative solutions, to guide clients across the healthcare and life sciences industry on:

  • Development and execution of market access strategies for new and existing technologies
  • Advocacy with Congress and federal and state agencies, including the Centers for Medicare and Medicaid Services (CMS)
  • Medicare and Medicaid coverage, coding, and reimbursement matters
  • Compliance with billing policies
  • Federal and state fraud and abuse laws, including development of compliance programs
  • Federal and state “sunshine” laws
  • Complex litigation matters, including government audits and investigations, qui tam lawsuits, and other matters involving the HHS Office of Inspector General (OIG), US Department of Justice, and CMS Center for Program Integrity

Mr. Greig also advises private equity firms, investment banks, venture capital funds, commercial lenders, and healthcare and life science companies on regulatory issues related to mergers and acquisitions, IPOs, and US financings.

Mr. Greig is a member of the American Health Law Association and the American Bar Association Health Law Section. 

A recognized thought leader, Mr. Greig regularly writes and speaks on healthcare and life sciences topics. He co-authored a chapter related to Medicare and Medicaid reimbursement for off-label uses of drugs and devices in Off-Label Communications: A Guide to Sales & Marketing Compliance, published by the Food and Drug Law Institute (FDLI), and presents on healthcare regulatory and reimbursement topics at national conferences organized by leading industry organizations including AdvaMed, PhRMA, the American Health Law Association (AHLA), the Medical Device Manufacturers Association (MDMA), the 8400 Health Network, and the California Life Sciences Institute.

Mr. Greig's experience includes advising:

Regulatory Advocacy

  • A regional healthcare provider system on establishing a “hospital at home” program to deliver inpatient-level care to patients in their homes during the COVID-19 public health emergency (PHE)
  • A publicly traded global life sciences company on: 
    • Expanding national Medicare coverage policies for continuous glucose monitoring (CGM) systems
    • Advocacy to successfully reverse a proposed Medicare payment reduction to CGMs 
  • A leading national dialysis organization on modifying a value-based care payment model from the Center for Medicare and Medicaid Innovation (CMMI)
  • A non-opioid drug manufacturer on coordinating a government affairs strategy that established new Medicare add-on payment pathways for non-opioid pain management treatments used in hospitals and ASCs
  • A publicly traded medical technology company on reversing negative Medicare coverage policies for procedures involving the company’s flagship glaucoma treatment technology 
  • A group of government agencies in the Middle East, on:
    • Designing and implementing an innovative, value-based healthcare ecosystem 
    • Drafting laws and regulations governing the structure of a new health insurance and reimbursement system
  • Multiple Israel-based healthcare and life sciences companies on:
    • Healthcare regulatory counseling related to US-based clinical trial and commercialization matters
    • Reimbursement and market access strategy for the launch of molecular diagnostic tests 
  • A nonprofit clinical trade association on reversing Medicare coverage policies that would have created barriers to patient access to advanced wound care therapies
  • A leading healthcare services provider on activity within the provider’s venture investment division 
  • The Coalition of Manufacturers of Speech Generating Devices on favorably expanding the scope of a Medicare National Coverage Determination (NCD)
  • A group of pharmaceutical manufacturers on finalizing appropriate Medicare payment policies for novel drugs approved through FDA’s 505(b)(2) pathway

New Product Recognition

  • AppliedVR, a digital health company focused on virtual reality-based solutions to treat chronic pain, on obtaining Medicare recognition, unique coding, and appropriate payment for its breakthrough VR device 
  • The developer of a breakthrough treatment for advanced metastatic cancer on obtaining New Technology APC designation and payment for an algorithm-based treatment planning procedure and advanced radiation therapy delivery procedure performed with the company’s technology
  • Magnus Medical on market access activities for the company’s novel brain stimulation technology for treatment-resistant major depressive disorder
  • Cala Health, a leader in bioelectronic medicine, on establishing unique coding, preferred payment, and national Medicare coverage for its advanced neuromodulation system to treat Parkinson’s disease and essential tremor symptoms
  • The developer of an AI-based diagnostic software solution on obtaining New Technology Add-on Payment (NTAP) and commercializing the product 
  • Vektor Medical on establishing a new CPT code to report its machine-learning algorithm for noninvasive cardiac analysis
  • A precommercial medical device manufacturer on obtaining coverage for its clinical trial procedures under Medicare’s Category B IDE Trial NCD
  • A medical device company on achieving new coding and desired payment levels after an initial denial of insurance recognition for its product due to its app-based mechanism of action
  • Multiple pharmaceutical manufacturers on obtaining new codes and establishing coverage for infused and injected products


  • Patient Square Capital on its:
    • US$1.25 billion acquisition of Hanger
    • US$300 million acquisition of SOC Telemed
    • Acquisition of Summit BHC
  • KKR on its:
    • US$2.8 billion acquisition of WebMD
    • US$1.4 billion acquisition of PharMerica
    • Acquisition of Covenant Surgical Partners
  • Leonard Green & Partners on its:
    • US$2.2 billion acquisition of ExamWorks Group
    • Purchase of a majority stake in MDVIP
  • US Renal Care on its: 
    • Acquisition of DSI Renal
    • Sale to a private investor group led by Bain Capital
  • Access TeleCare on acquiring Forefront Telecare
  • Galen Partners on acquiring Wings Recovery Holdings
  • BlueSprig Holdings, a KKR portfolio company, on acquiring Trumpet Behavioral Health

Litigation and Investigations

  • A cardiac monitoring device manufacturer on obtaining a declination from DOJ following an investigation into the company’s referral relationships and market access activities
  • A leading academic medical center on responding to an OIG audit and reducing alleged overpayment liability by more than 80%
  • A group of nationally recognized hospitals on False Claims Act litigation related to Medicare claims involving cardiac rhythm devices
  • A large health system on complying with the obligations of a corporate integrity agreement with the DOJ and HHS OIG
  • A national network of oncology treatment centers on obtaining a declination from DOJ on an investigation into coding and billing practices and practice management fee arrangements

Bar Qualification

  • District of Columbia
  • Ohio


  • JD, The University of Texas School of Law, 2010
    high honors
  • BS, The Ohio State University, 2006
    cum laude